Pearls and Pitfalls in Interpreting PSMA-Targeted PET/CT Imaging
Sponsored by the SNMMI PET Center of Excellence
Twyla Bartel, DO, MBA, FACNM
Katherine Zukotynski, MD, FACNM
Ashwin Parihar, MBBS, MD
Mallinkrodt Institute of Radiology
This session comprises a case-based discussion, focusing on scan interpretation and common pitfalls associated with Prostate-Specific Membrane Antigen (PSMA) targeted PET imaging for prostate cancer. The primary pitfalls associated with PSMA imaging result from its non-specificity towards carcinoma of prostatic origin. While the primary focus will be on 68Ga-PSMA-11, other tracers such as 18F-labeled PSMA ligands will be briefly discussed. It is expected that with the recent FDA approval, several centers would perform PSMA imaging in routine clinical practice, and this webinar will help in avoiding the pitfalls as well as emphasize the potential novel applications of this radiotracer.
1. Describe the physiologic biodistribution of 68Ga- and 18F-labeled PSMA radiotracers and common patterns of localized primary, regional nodal, and distant metastatic disease.
2. Review the common and uncommon pitfalls described according to the anatomic sites that are commonly involved by metastatic prostate cancer and discuss some useful tips to help avoid them.
3. Discuss how several of the pitfalls are being utilized for novel applications of this radiotracer
CE Credit applications for physicians, pharmacists, physicists and technologists are pending.